Gary. E. Raskob
#124,799
Most Influential Person Now
Gary. E. Raskob's AcademicInfluence.com Rankings
Gary. E. Raskobmedical Degrees
Medical
#1974
World Rank
#2362
Historical Rank
Public Health
#278
World Rank
#288
Historical Rank
Epidemiology
#328
World Rank
#345
Historical Rank
Download Badge
Medical
Gary. E. Raskob's Degrees
- PhD Epidemiology University of North Carolina at Chapel Hill
- Masters Epidemiology University of North Carolina at Chapel Hill
- Bachelors Biology University of North Carolina at Chapel Hill
Similar Degrees You Can Earn
Why Is Gary. E. Raskob Influential?
(Suggest an Edit or Addition)Gary. E. Raskob's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Oral rivaroxaban for symptomatic venous thromboembolism. (2010) (2225)
- Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (2079)
- Oral apixaban for the treatment of acute venous thromboembolism. (2013) (1942)
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) (1713)
- Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. (2013) (1643)
- Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. (1996) (1598)
- Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (1348)
- Hemorrhagic complications of anticoagulant treatment. (1992) (1263)
- Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. (2006) (1215)
- Apixaban for extended treatment of venous thromboembolism. (2013) (1134)
- Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. (2010) (1028)
- American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. (2007) (953)
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial (2010) (762)
- Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. (1986) (747)
- Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. (2010) (737)
- Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. (1982) (727)
- Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism (2017) (713)
- Apixaban or enoxaparin for thromboprophylaxis after knee replacement. (2009) (710)
- Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. (1992) (710)
- ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. (2003) (667)
- Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. (2009) (662)
- Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. (2003) (643)
- Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. (2006) (590)
- Thrombosis: A Major Contributor to Global Disease Burden (2014) (542)
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies (2013) (534)
- Global Burden of Thrombosis: Epidemiologic Aspects. (2016) (534)
- Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. (1983) (495)
- Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. (1990) (486)
- Thrombosis: A Major Contributor to Global Disease Burden (2014) (450)
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (2019) (414)
- Factor XI antisense oligonucleotide for prevention of venous thrombosis. (2014) (398)
- Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (367)
- A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. (1993) (366)
- Clinical features of paediatric pulmonary hypertension: a registry study (2012) (360)
- Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis (2004) (354)
- A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. (2008) (336)
- The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. (1999) (336)
- Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials (2011) (328)
- Drug-induced thrombocytopenia: a systematic review of published case reports. (1998) (327)
- This article has been cited by other articles (2003) (323)
- A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. (1994) (310)
- The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. (2016) (307)
- Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. (1985) (307)
- The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. (2011) (305)
- Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty (2001) (299)
- Idraparinux versus standard therapy for venous thromboembolic disease. (2007) (292)
- Idiopathic thrombocytopenic purpura: A concise summary of the pathophysiology and diagnosis in children and adults. (1998) (281)
- The Clinical Validity of Normal Compression Ultrasonography in Outpatients Suspected of Having Deep Venous Thrombosis (1998) (271)
- Optimal therapeutic level of heparin therapy in patients with venous thrombosis. (1992) (258)
- Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. (1997) (244)
- Hemorrhagic complications of anticoagulant treatment. (2004) (231)
- Sensitivity and Specificity of Helical Computed Tomography in the Diagnosis of Pulmonary Embolism (2000) (231)
- Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. (1990) (224)
- Thrombosis: a major contributor to global disease burden. (2014) (216)
- Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. (2000) (216)
- Thrombosis: a major contributor to the global disease burden (2014) (215)
- Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. (1990) (200)
- Hemorrhagic complications of long-term anticoagulant therapy. (1989) (194)
- Chronic idiopathic thrombocytopenic purpura. (1994) (190)
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (2018) (190)
- Prevention and treatment of venous thromboembolism--International Consensus Statement. (2013) (188)
- Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial (2015) (179)
- Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement (2001) (172)
- Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism (2000) (171)
- A new noninvasive management strategy for patients with suspected pulmonary embolism. (1989) (167)
- Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. (2001) (151)
- Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement (2010) (149)
- Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. (2010) (149)
- Aging and heparin-related bleeding. (1996) (146)
- Design of the REVEAL registry for US patients with pulmonary arterial hypertension. (2008) (145)
- Outcome Analysis for Lip Carcinoma (1995) (140)
- Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study (2018) (139)
- Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Thromboembolic Disease: American College Antithrombotic Therapy for Venous (2008) (139)
- Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. (2016) (138)
- Patients With Cancer (2013) (132)
- Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. (2003) (129)
- Prophylaxis of venous thromboembolism. An overview. (1986) (126)
- The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. (1997) (126)
- Prevention and Treatment of Venous Thromboembolism (2013) (125)
- Opinions regarding the diagnosis and management of venous thromboembolic disease. ACCP Consensus Committee on Pulmonary Embolism. American College of Chest Physicians. (1998) (122)
- Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. (1997) (119)
- Extended prophylaxis of venous thromboembolism with idraparinux. (2007) (116)
- Pulmonary embolism in outpatients with pleuritic chest pain. (1988) (115)
- Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. (1998) (111)
- Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis (2020) (107)
- Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. (2002) (105)
- Global public awareness of venous thromboembolism (2015) (104)
- Serial Impedance Plethysmography in Pregnant Patients with Clinically Suspected Deep-Vein Thrombosis: Clinical Validity of Negative Findings (1990) (102)
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. (2020) (100)
- Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials (2009) (98)
- Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. (1999) (97)
- Prophylaxis of venous thromboembolic disease following hip and knee surgery. (1986) (95)
- Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. (1997) (94)
- Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. (2012) (94)
- Clinical features and diagnosis of venous thrombosis. (1986) (93)
- Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. (2007) (92)
- Negative d-dimer Result To Exclude Recurrent Deep Venous Thrombosis: A Management Trial (2004) (89)
- A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis Against Deep-Vein Thrombosis After Hip or Knee Implantation (1994) (87)
- Venous thromboembolic disease (1991) (85)
- Edoxaban for treatment of venous thromboembolism in patients with cancer (2015) (85)
- Low-probability lung scan findings: a need for change. (1991) (84)
- Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. (2009) (83)
- Risks for Major Bleeding from Thrombolytic Therapy in Patients with Acute Pulmonary Embolism: Consideration of Noninvasive Management (1994) (82)
- Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials (2013) (81)
- Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care (2003) (75)
- The Economic Impact of Treating Deep Vein Thrombosis with Low-Molecular-Weight Heparin: Outcome of Therapy and Health Economy Aspects (1998) (73)
- Epidemiology and pathogenesis of venous thrombosis. (1986) (72)
- Prevention of central venous catheter-associated thrombosis: a meta-analysis. (2007) (71)
- Abelacimab for Prevention of Venous Thromboembolism. (2021) (67)
- Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis (2011) (67)
- The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE (2016) (66)
- Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials (2007) (64)
- The low-probability lung scan. A need for change in nomenclature. (1995) (64)
- Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q©) (2009) (62)
- Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial (2012) (60)
- Challenges in the diagnosis of acute pulmonary embolism. (2008) (59)
- Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. (2000) (59)
- Milvexian for the Prevention of Venous Thromboembolism. (2021) (58)
- Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. (2000) (57)
- Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. (2016) (55)
- Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study (2019) (55)
- The diagnosis of clinically suspected venous thrombosis. (1984) (54)
- Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults (1998) (52)
- Oral anticoagulant therapy (1996) (49)
- Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. (2019) (48)
- New paradigms in venous thromboprophylaxis of medically ill patients (2017) (48)
- Physician-guided treatment compared with a heparin protocol for deep vein thrombosis. (1994) (45)
- The diagnosis of clinically suspected pulmonary embolism. Practical approaches. (1986) (44)
- Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis (2014) (44)
- Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery (2012) (44)
- Dose-Response Study of Recombinant Factor VIIa / Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c 2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement (2001) (41)
- Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. (2000) (41)
- Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. (2004) (40)
- Different effects of heparin in males and females. (1998) (39)
- Idiopathic thrombocytopenic purpura: diagnosis and management. (1998) (38)
- Thrombosis: A major contributor to global disease burden (2014) (38)
- Chemical (VX) terrorist threat: public knowledge, attitudes, and responses. (2004) (38)
- Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients (2020) (38)
- Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. (2000) (37)
- Diagnosis of pulmonary embolism. (1995) (37)
- Duplex Ultrasonography for the Detection of Deep Vein Thrombi After Total Hip or Knee Arthroplasty (1993) (35)
- Diversity and severity of adverse reactions to quinine: A systematic review (2016) (35)
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery (2010) (34)
- Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study (2019) (34)
- Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists (2017) (33)
- Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism (2016) (32)
- Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups (2013) (30)
- APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL (2014) (30)
- Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. (2016) (29)
- Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial (2008) (27)
- Clinical implications of incidental venous thromboembolism in cancer patients (2019) (26)
- The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations (2018) (26)
- Global Burden of Thrombosis (2016) (26)
- Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients (2013) (25)
- A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. (1984) (25)
- Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. (2016) (25)
- Cost Effectiveness of Diagnosis of Deep Vein Thrombosis in Symptomatic Patients (1995) (24)
- Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin (2008) (24)
- Effect of treatment with low-dose warfarin-aspirin on activated factor VII. (1995) (24)
- Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. (2002) (23)
- Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. (2016) (23)
- Diagnosis of pulmonary embolism. (1986) (22)
- Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the Van Gogh DVT trial (2010) (22)
- Venous thromboembolism : an evidence-based atlas (1996) (22)
- Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. (2020) (22)
- Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists (2017) (21)
- Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. (1994) (21)
- Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists (2016) (21)
- Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. (2018) (20)
- American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. (2007) (20)
- Hemorrhagic complications of anticoagulant treatment. (2001) (20)
- Methodological guidelines for clinical trials evaluating new therapeutic approaches in bone and joint surgery. (1985) (19)
- Thrombotic Complications of Antithrombotic Therapy: A Paradox with Implications for Clinical Practice (1997) (19)
- Inferior Vena Cava Filters (2013) (17)
- Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients (2021) (17)
- Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. (1998) (17)
- Importance of subsegmental pulmonary embolism. (2013) (16)
- A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. (2004) (16)
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. (2016) (16)
- Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy (2015) (16)
- Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials (2020) (16)
- Injury Prevention and Control Research and Training in Accredited Schools of Public Health: A CDC/ASPH Assessment (2006) (16)
- Study DVT Dose-Ranging - symptomatic deep vein thrombosis: the Einstein factor Xa inhibitor rivaroxaban in the treatment of patients with acute A dose-ranging study evaluating once-daily oral administration of the (2013) (15)
- Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study (2018) (15)
- RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate (2016) (15)
- The economics of venous thromboembolism prophylaxis: a primer for clinicians. (2003) (15)
- The US Cancer Moonshot initiative. (2016) (15)
- Gynecology and Obstetrics (2013) (15)
- Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. (2019) (14)
- Pharmacokinetics and Dynamics of Heparin in Patients with Proximal Vein Thrombosis (1989) (14)
- Predicting the Daily Prothrombin Time Response to Warfarin (1990) (14)
- The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. (2015) (14)
- Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin (2016) (13)
- Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients (2016) (13)
- Hemorrhagic complications of long-term anticoagulant therapy. (1989) (13)
- Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. (2017) (12)
- Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial (2019) (12)
- Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism (2021) (12)
- Risk of haemorrhage associated with long term anticoagulant therapy (1985) (12)
- Superficial Vein Thrombosis (2013) (11)
- Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma (2021) (11)
- Pulmonary embolism among patients with a nearly normal ventilation/perfusion lung scan. (1996) (10)
- Diagnosis and management of pulmonary thromboembolism. (1990) (10)
- A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism (2004) (10)
- Treatment for Patients With Cancer (2013) (10)
- Heparin therapy for venous thrombosis and pulmonary embolism. (1988) (10)
- Anticoagulant therapy for venous thromboembolism. (1989) (10)
- ISTH Steering Committee for World Thrombosis Day The members of the ISTH Steering Committee for World Thrombosis Day (2014) (10)
- Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients (2003) (9)
- On World Thrombosis Day (2014) (9)
- Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective (2020) (9)
- Global public awareness about atrial fibrillation (2017) (9)
- Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis‐Atrial Fibrillation Study (2014) (9)
- Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. (2009) (8)
- Guidelines: Report From an American College of Chest Physicians Task Force Grading Strength of Recommendations and Quality of Evidence in Clinical (2006) (8)
- Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis (2021) (8)
- Edoxaban for Cancer-Associated Venous Thromboembolism. (2018) (7)
- Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study (2019) (7)
- REVEAL REGISTRY: BASELINE CHARACTERISTICS OF THE FIRST 1,226 ENROLLED PATIENTS (2007) (7)
- Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation (2008) (7)
- Diagnosis and Anticoagulant Treatment * (2013) (7)
- Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study (2017) (7)
- Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. (1999) (7)
- Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism (2012) (7)
- Low molecular weight heparin (logiparin™) compared with less intense warfarin prophylaxis against venous thromboembolism following major elective hip surgery (1992) (6)
- Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 Trials (2010) (6)
- Medical patients. (2013) (6)
- A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study (2017) (6)
- The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications. (1999) (6)
- Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial (2018) (5)
- Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer (2007) (5)
- On World Thrombosis Day. (2014) (5)
- Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. (1996) (5)
- The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Mole Molecular-Weight Heparin Compared with Continuous Intravenous Heparin (1995) (5)
- Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data (2014) (5)
- Hirudin versus heparin and low-molecular-weight heparin: and the winner is... (1998) (5)
- Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER (2021) (5)
- A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH) (2008) (5)
- Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban (2021) (4)
- ACCP Conference on Antithrombotic and Thrombolytic Therapy Antithrombotic Therapy for Venous Thromboembolic Disease : The Seventh (2004) (4)
- Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score (2023) (4)
- Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials (2022) (4)
- Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis (2019) (4)
- Treatment of Venous Thromboembolism (1994) (4)
- The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. (2018) (4)
- Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial (2018) (3)
- 708: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Pulmonary Vascular Disease Associated with Congenital Heart Disease (2009) (3)
- Risk of Haemorrhage Associated with Long Term (1985) (3)
- Prevention of Central Venous Catheter-Associated (2007) (3)
- Cost-Effectiveness of Prevention and Treatment of VTE (2013) (3)
- MULTINATIONAL DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH ANTI-COAGULANT TREATMENT (2007) (3)
- Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent (2018) (3)
- ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL (2014) (3)
- Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review (2003) (3)
- Abstract 12863: Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis of Mortality and Major Thromboembolic Events in 16,496 Patients From the MAGELLAN and MARINER Trials (2019) (3)
- Heparin in the initial treatment of venous thrombosis. (1990) (3)
- 228: REVEAL Registry: Comparison of Patients with Childhood-Onset and Adult-Onset Idiopathic Pulmonary Arterial Hypertension (2009) (3)
- Clinical decisions in idiopathic thrombocytopenic purpura. (1997) (2)
- Prevention of Venous Thrombosis in General Surgery and Orthopaedics (1995) (2)
- Low molecular weight heparin, heparin, and warfarin (1995) (2)
- Long-term oral anticoagulant therapy for coronary artery disease. (1993) (2)
- OC-14 Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study (2021) (2)
- Abstract 10541: Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study (2018) (2)
- LMW heparin for deep vein thrombosis. (1991) (2)
- Surgical thrombectomy. (2013) (2)
- Combined Modalities in Surgical Patients (2013) (2)
- #613 Self‐reported initial management approaches for childhood idiopathic thrombocytopenic purpura (ITP): results of a survey of members of The American Society of Pediatric Hematology/Oncology (ASPH/O) (1998) (2)
- General, Vascular, Bariatric, and Plastic Surgical Patients (2013) (2)
- Impedance plethysmography for suspected deep-vein thrombosis. (1995) (2)
- 397: REVEAL Registry: Pediatric IPAH Versus Pediatric Pulmonary Vascular Disease Associated with Congenital Heart Disease (2009) (2)
- COMPARISON OF JNJ9375, A THROMBIN EXOSITE 1-DIRECTED ANTIBODY, WITH APIXABAN FOR THROMBOPROPHYLAXIS AFTER ELECTIVE KNEE REPLACEMENT SURGERY: TEXT-TKR STUDY (2019) (2)
- Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]. (2020) (2)
- Preventing systemic embolism in patients with abnormal ventricular function. (1994) (2)
- Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial (2022) (1)
- Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial (2019) (1)
- Global public awareness of venous thromboembolism: reply (2016) (1)
- Hip Surgery and Venous Thrombosis: Effect of Anesthesia-Reply (1990) (1)
- Thrombophilia (2013) (1)
- Thrombolytic Therapy (2013) (1)
- Orthopedic Surgery and Trauma (2013) (1)
- Low molecular weight heparin in the prevention and treatment of venous thromboembolism (1996) (1)
- The Problem and the Need for Prevention (2013) (1)
- Critical Care Medical Patients (2013) (1)
- A noninvasive approach for the treatment of patients with suspected pulmonary embolism (2004) (1)
- Oral anticoagulants: new and improved. (2014) (1)
- Impact of World Thrombosis Day campaign (2017) (1)
- Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness (2022) (1)
- Hemorrhagic complications of anticoagulant treatment. (1998) (1)
- Hemodynamic characterization at diagnosis in children with Pulmonary Hypertension (PH): insights from the global TOPP registry (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) (2011) (1)
- Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older (2021) (1)
- Warfarin prophylaxis after knee or hip surgery was more cost-effective than tinzaparin in the United States but not in Canada (1997) (1)
- Impedance Plethysmography and DVT Diagnosis (1993) (1)
- Guidelines for Idiopathic Thrombocytopenic Purpura (1997) (1)
- Prevention of venous thrombosis and pulmonary embolism following orthopedic surgery (1993) (1)
- Hospital Associated Venous Thromboembolism in Oklahoma County (2016) (1)
- Thromboprophylaxis after Hospitalization for Medical Illness. (2018) (1)
- Thrombolytic Therapy ACCP Conference on Antithrombotic and Thromboembolic Disease : The Seventh Antithrombotic Therapy for Venous (2004) (1)
- Key Questions to be Answered (2013) (1)
- Positive predictive value of compression ultrasound for deep-vein thrombosis in symptomatic outpatients: Importance of the site of vein non-compressibility (1998) (0)
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors (2023) (0)
- Urologic Surgery (2013) (0)
- Anticoagulants and thrombolysis in the treatment of pulmonary embolism. (1995) (0)
- 64 DIAGNOSIS OF SUSPECTED RECURRENT DEEP-VEIN THROMBOSIS USING D-DIMER AND COMPRESSION ULTRASONOGRAPHY. (2004) (0)
- Morning Plenary Session: Holding Fast to Dreams Freeman A. Hrabowski III , President, University of Maryland Baltimore (2016) (0)
- Incidence and characteristics of cancer-associated thrombosis in a racially diverse population: A population-based study. (2019) (0)
- Venous Thrombosis (2019) (0)
- #612 Attitudes about participation in a randomized trial of alternate initial treatments of childhood idiopathic thrombocytopenic purpura (ITP): results of a survey of members of The American Society of Pediatric Hematology/Oncology (ASPH/O) (1998) (0)
- Incidence of Venous Thromboembolism Estimated Using Hospital Discharge Data: Differences Between Event-Based Estimates and Patient-Based Estimates (2014) (0)
- Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies (2019) (0)
- Duration of anticoagulant treatment for venous thrombosis (1997) (0)
- Exploring the applicability of using natural language processing to support nationwide venous thromboembolism surveillance (Preprint) (2022) (0)
- Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial (2019) (0)
- IMPEDANCE PLETHYSMOGRAPHY FOR SUSPECTED DEEP-VEIN THROMBOSIS. AUTHORS' REPLY (1995) (0)
- Safety of withholding anticoagulation in outpatients with suspected deep-vein thrombosis and normal compression ultrasonography (1998) (0)
- Meta-analysis: LMWH is effective in reducing recurrent thromboembolism, bleeding, and death in acute DVT (1996) (0)
- 51 SYSTEMATIC REVIEW OF CATHETER-ASSOCIATED DEEP VEIN THROMBOSIS PREVENTION (2005) (0)
- Frequency of a normal lung scan observed in the urokinase-streptokinase pulmonary embolism trial. (1987) (0)
- Title Page / Table of Contents, Vol. 23, Supplement 1, 1993 (1993) (0)
- Duration of warfarin in pulmonary embolism. (2006) (0)
- Thromboprophylaxis in Pregnancy, Orthopaedic Surgery Patients and in Long-Term Strategies (1998) (0)
- The current status and future directions of impedance cardiography in ICU (2006) (0)
- Abelacimab for Prevention of Venous Thromboembolism. Reply. (2021) (0)
- CHARACTERIZATION OF 6,122 PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM IN ROUTINE CLINICAL PRACTICE: RE-COVERY DVT/PETM PROSPECTIVE GLOBAL COHORT STUDY (2018) (0)
- Clinical Likelihood Among Patients With Nearly Normal V / Q Scans Comparing Patients With Conditions Diagnosed by Angiography or Outcome Analysis * Clinical (0)
- Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis (2018) (0)
- Initial and Long‐Term Treatment of Deep Vein Thrombosis (2009) (0)
- Practical Approaches for Preventing Venous Thromboembolism (2019) (0)
- revention of Central Venous Catheter-Associated hrombosis : A Meta-analysis (2007) (0)
- Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems (2019) (0)
- Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study (2022) (0)
- 222 Right Heart Catheterization in Patients with Pulmonary Arterial Hypertension: Practice Patterns Observed in the REVEAL Registry (2011) (0)
- Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis (2021) (0)
- Sensitivity and Specificity of Ultrasonography in the Diagnosis of Upper Extremity Deep Vein Thrombosis (2017) (0)
- Which Drugs Cause Thrombocytopenia (1999) (0)
- Logistics of double-blinding a randomized trial of intravenous vs. subcutaneous heparin for the treatment of venous thrombosis (1984) (0)
- The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. (2017) (0)
- communications to the editorLung Scintigraphy (1987) (0)
- TREATMENT OF DEEP VENOUS THROMBOSIS AND ECONOMIC ASPECTS (1987) (0)
- Other Uses of LMWHs – Miscellaneous (1998) (0)
- Apixaban for Extended Treatment of Venous Thromboembolism (2013) (0)
- Subject Index, Vol. 23, 1993 (1993) (0)
- GUIDELINES FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA. AUTHORS' REPLY (1997) (0)
- Prevention of Postthrombotic Syndrome (2013) (0)
- Establishing a Pilot Surveillance System for Venous Thromboembolism (2014) (0)
- Risks for Bleeding in Patients with Pulmonary Embolism Treated with Thrombolytic Agents (1995) (0)
- Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement (1997) (0)
- Exploring the Applicability of Using Natural Language Processing to Support Nationwide Venous Thromboembolism Surveillance: Model Evaluation Study (2022) (0)
- The EINSTEIN DVT Study: Does Localization of the Initial DVT Affect the Occurrence of Recurrent VTE While Patients Are on Anticoagulation? (2011) (0)
- Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. (2022) (0)
- Cost-effective Approaches to the Diagnosis of Pulmonary Embolism-Reply (1996) (0)
- Time course of recurrent venous thromboembolic and major bleeding events during anticoagulant therapy with apixaban or enoxaparin/warfarin: analysis of the amplify data using landmark method (2014) (0)
- In Reply: Testing For Pulmonary Embolism (1990) (0)
- To the EditorTo the Editor (2006) (0)
- Differential Diagnosis of Symptoms and Signs of Venous Thrombosis (2010) (0)
- Abstract 16110: Impact of Institutional Volume on In-hospital Mortality and Resource Utilization Among Patients With Pulmonary Embolism Treated With Catheter Directed Thrombolysis: A Population-Based Cohort Study (2020) (0)
- Abstracts of papers Rational use of drugs (1989) (0)
- Risk Factors and Coagulation Disorders – LMWH Pharmacokinetics and Pharmacodynamics (1998) (0)
- Long-term anticoagulant therapy prevents recurrent venous thromboembolism. (1982) (0)
- Impact of Thrombocytopenia on Bleeding and Recurrent Thrombosis in Cancer Associated Thrombosis: A Post Hoc Analysis of Hokusai VTE Cancer Study (2022) (0)
- Mechanism for double-blinding a randomized trial of short- vs. long-course intravenous heparin therapy for venous thrombosis (1986) (0)
- RECURRENT VENOUS THROMBOEMBOLISM IN PULMONARY EMBOLISM PATIENTS WITH RIGHT VENTRICULAR DYSFUNCTION IN THE HOKUSAI-VTE STUDY (2016) (0)
- A Need for Change in Nomenclature (2017) (0)
- UvA-DARE ( Digital Academic Repository ) Venous thromboembolism , coagulation and cancer (2009) (0)
- Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County (2019) (0)
- in a prospective cohort of 142 patients uremic syndrome: relation to presenting features and clinical outcomes hemolytic - ADAMTS13 activity in thrombotic thrombocytopenic purpura (2013) (0)
- Characteristics From the REVEAL Registry Pulmonary Arterial Hypertension : Baseline (2010) (0)
- Risk of Severe Bleeding with Rivaroxaban in Medically Ill Patients with Bronchiectasis (2019) (0)
- Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population (2022) (0)
- Helical Computed Tomography for Diagnosing Pulmonary Embolism (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gary. E. Raskob?
Gary. E. Raskob is affiliated with the following schools:
